Search results for "Pyrazine"

showing 10 items of 325 documents

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.

2013

A sequential approach including bortezomib induction, intermediate-dose melphalan, and autologous stem cell transplantation (ASCT), followed by lenalidomide consolidation-maintenance, has been evaluated. Efficacy and safety data have been analyzed on intention-to-treat and results updated. Newly diagnosed myeloma patients 65 to 75 years of age (n = 102) received 4 cycles of bortezomib-pegylated liposomal doxorubicin-dexamethasone, tandem melphalan (100 mg/m(2)) followed by ASCT (MEL100-ASCT), 4 cycles of lenalidomide-prednisone consolidation (LP), and lenalidomide maintenance (L) until disease progression. The complete response (CR) rate was 33% after MEL100-ASCT, 48% after LP and 53% after…

OncologyMelphalanMalemedicine.medical_specialtyImmunologyBortezomib-induction/Mel100-ASCT/lenalidomide consolidation-maintenance is effective in elderly patients with excellent performance status. Deaths related to AEs were higher in patients $70 years suggesting the need of a more careful patient selection.BiochemistryTransplantation AutologousDexamethasoneDisease-Free SurvivalDrug Administration SchedulePolyethylene GlycolsBortezomibAutologous stem-cell transplantationRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdverse effectLenalidomideMelphalanDexamethasoneMultiple myelomaLenalidomideAgedBortezomib-induction/Mel100-ASCT/lenalidomide consolidation-maintenance is effective in elderly patients with excellent performance status. Deaths related to AEs were higher in patients $70 yearsbusiness.industryBortezomibCell BiologyHematologyMiddle Agedmedicine.diseasesuggesting the need of a more careful patient selectionBoronic AcidsSurgeryThalidomideTransplantationTreatment OutcomeDoxorubicinPyrazinesDisease ProgressionFemalebusinessMultiple Myelomamedicine.drugStem Cell Transplantation
researchProduct

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

2015

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular deat…

Oralmedicine.medical_specialtyHeart diseasesGlycosylatedAdministration Oralheart failureType 2 diabetesDipeptidyl peptidase-4 inhibitorKaplan-Meier EstimatePlaceboSitagliptin PhosphateSitagliptin Cardiovascular Outcomeschemistry.chemical_compoundDrug TherapyDouble-Blind MethodInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentsGlycated HemoglobinHemoglobin A GlycosylatedAdministration Oral; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Drug Therapy Combination; Follow-Up Studies; Heart Diseases; Heart Failure; Hemoglobin A Glycosylated; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles; Medicine (all)business.industryMedicine (all)SemaglutideSitagliptin PhosphateHemoglobin AGeneral MedicineTriazolesta3121medicine.diseaseSurgeryHospitalizationCardiovascular diseaseschemistryDiabetes Mellitus Type 2SitagliptinPyrazinesAdministrationCombinationDrug Therapy CombinationGlycated hemoglobinbusinessType 2Alogliptinmedicine.drugFollow-Up StudiesNew England Journal of Medicine
researchProduct

Guest Modulation of Spin-Crossover Transition Temperature in a Porous Iron(II) Metal Organic Framework: Experimental and Periodic DFT Studies

2014

The synthesis, structure, and magnetic properties of three clathrate derivatives of the spin-crossover porous coordination polymer {Fe(pyrazine)[Pt(CN)(4)]} (1) with five-membered aromatic molecules furan, pyrrole, and thiophene is reported. The three derivatives have a cooperative spin-crossover transition with hysteresis loops 14-29 K wide and average critical temperatures T-c=201 K (1.fur), 167 K (1.pyr), and 114.6 K (1.thio) well below that of the parent compound 1 (T-c=295 K), confirming stabilization of the HS state. The transition is complete and takes place in two steps for 1.fur, while 1.pyr and 1.thio show 50% spin transition. For 1.fur the transformation between the HS and IS (mi…

Phase transitionPyrazineMetal–organic frameworksTransition temperatureOrganic ChemistrySpin transitionSpace groupGeneral ChemistryCatalysisSpin-crossover compoundsCrystallographychemistry.chemical_compoundTetragonal crystal systemDensity functional calculationsHofmann clathrateschemistryComputational chemistrySpin crossoverFISICA APLICADAMagnetic propertiesOrthorhombic crystal system
researchProduct

The Role of the Low-Lying $$n\pi ^*$$ n π ∗ States on the Photophysics of Pyrazine

2016

In this chapter, the theoretical tools introduced in Chaps. 2 and 4 are applied to the study of the non-adiabatic relaxation dynamics of pyrazine after ultraviolet (UV) excitation.

Physics010304 chemical physicsPyrazineRelaxation (NMR)Transition dipole moment010402 general chemistryPhotochemistrymedicine.disease_cause01 natural sciences0104 chemical scienceschemistry.chemical_compoundchemistry0103 physical sciencesmedicinePiBright stateExcitationUltraviolet
researchProduct

Theoretical Tools for the Description of Strong Field Laser-Molecule Interaction

2016

In this chapter, the main theoretical tools used in the work presented in the next two chapters on the laser control of the radiationless decay in pyrazine and of the tunneling dynamics in NHD\(_2\), are introduced.

PhysicsWork (thermodynamics)PyrazineStrong fieldLaserlaw.inventionchemistry.chemical_compoundGeometric phasechemistrylawMoleculeAtomic physicsRabi frequencyQuantum tunnelling
researchProduct

Apoptosis: a relevant tool for anticancer therapy.

2006

Apoptosis is a form of cell death that permits the removal of damaged, senescent or unwanted cells in multicellular organisms, without damage to the cellular microenvironment. Defective apoptosis represents a major causative factor in the development and progression of cancer. The majority of chemotherapeutic agents, as well as radiation, utilize the apoptotic pathway to induce cancer cell death. Resistance to standard chemotherapeutic strategies also seems to be due to alterations in the apoptotic pathway of cancer cells. Recent knowledge on apoptosis has provided the basis for novel targeted therapies that exploit apoptosis to treat cancer. These new target include those acting in the ext…

Programmed cell deathSettore MED/06 - Oncologia MedicaSurvivinAntineoplastic AgentsApoptosisLigandsInhibitor of Apoptosis ProteinsBortezomibTNF-Related Apoptosis-Inducing Ligandchemistry.chemical_compoundSulindacExisulindNeoplasmsSurvivinmedicineAnimalsHumansbusiness.industryBortezomibapoptosis TRAIL/Apo2L apoptin/VP3 ONYX015 Bortezomib exisulind survivinCancerReceptors Death DomainHematologymedicine.diseaseBoronic AcidsNeoplasm ProteinsOncologyProteasomechemistryApoptosisPyrazinesCancer cellCancer researchCapsid ProteinsbusinessMicrotubule-Associated Proteinsmedicine.drug
researchProduct

MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib

2014

The c-MYC (MYC afterward) oncogene is well known for driving numerous oncogenic programs. However, MYC can also induce apoptosis and this function of MYC warrants further clarification. We report here that a clinically relevant proteasome inhibitor significantly increases MYC protein levels and that endogenous MYC is necessary for the induction of apoptosis. This kind of MYC-induced cell death is mediated by enhanced expression of the pro-apoptotic BCL2 family members NOXA and BIM. Quantitative promoter-scanning chromatin immunoprecipitations (qChIP) further revealed binding of MYC to the promoters of NOXA and BIM upon proteasome inhibition, correlating with increased transcription. Both pr…

Programmed cell deathTranscription GeneticEGR1ApoptosisBiologyBortezomibProto-Oncogene Proteins c-mycMicehemic and lymphatic diseasesCell Line TumorProto-Oncogene ProteinsGeneticsmedicineAnimalsPromoter Regions GeneticTranscription factorCells CulturedEarly Growth Response Protein 1Zinc finger transcription factorBinding SitesOncogeneBcl-2-Like Protein 11Genes p16Gene regulation Chromatin and EpigeneticsMembrane ProteinsPromoterGenes p53Boronic AcidsChromatinddc:Gene Expression Regulation NeoplasticProto-Oncogene Proteins c-bcl-2PyrazinesCancer researchProteasome inhibitorApoptosis Regulatory ProteinsProteasome Inhibitorsmedicine.drug
researchProduct

Bortezomib Partially Improves Laminin α2 Chain–Deficient Muscular Dystrophy

2014

Congenital muscular dystrophy, caused by mutations in LAMA2 (the gene encoding laminin α2 chain), is a severe and incapacitating disease for which no therapy is yet available. We have recently demonstrated that proteasome activity is increased in laminin α2 chain-deficient muscle and that treatment with the nonpharmaceutical proteasome inhibitor MG-132 reduces muscle pathology in laminin α2 chain-deficient dy(3K)/dy(3K) mice. Here, we explore the use of the selective and therapeutic proteasome inhibitor bortezomib (currently used for treatment of relapsed multiple myeloma and mantle cell lymphoma) in dy(3K)/dy(3K) mice and in congenital muscular dystrophy type 1A muscle cells. Outcome measu…

Proteasome Endopeptidase ComplexApoptosisBiologyPathology and Forensic MedicineBortezomibmedicineAnimalsMyocyteMuscular dystrophyCells CulturedMultiple myelomaMuscle CellsMyogenesisBortezomibMusclesBody WeightMuscular Dystrophy Animalmedicine.diseaseBoronic AcidsFibrosisSurvival AnalysisMice Inbred C57BLDisease Models AnimalMicroRNAsGene Expression RegulationOrgan SpecificityPyrazinesCongenital muscular dystrophyCancer researchProteasome inhibitorMantle cell lymphomaLamininLocomotionmedicine.drugThe American Journal of Pathology
researchProduct

Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors

2014

Abstract A new series of pseudopeptide boronate proteasome inhibitors (2–3) was developed, through optimization of our previously described analogs of bortezomib, bearing a bicyclic 1,6-naphthyridin-5(6H)-one scaffold as P3 fragment (1). The biological evaluation on human 20S proteasome displayed a promising inhibition profile, especially for compounds bearing a P2 ethylene fragment, which exhibited Ki values in the nanomolar range for the ChT-L activity (e.g. 2a, Ki = 0.057 μM) and considerable selectivity for proteasome over bovine pancreatic α-chymotrypsin. Docking experiments into the yeast 20S proteasome revealed that the ligands are accommodated predominantly into the ChT-L site and t…

Proteasome Endopeptidase ComplexProtein ConformationStereochemistryPeptidomimeticAntineoplastic AgentsPeptidomimetic boronatePeptidomimetic boronates; Docing studies; Proteasome inhibitorsBortezomibchemistry.chemical_compoundCell Line TumorEndopeptidasesDrug DiscoverymedicineAnimalsHumansProteasome inhibitoranticancer drugTrypsinThreonineCell ProliferationPharmacologybiologyBicyclic moleculeBortezomibHydrolysisOrganic ChemistryActive siteGeneral MedicineBoronic AcidsCombinatorial chemistryMolecular Docking SimulationchemistryProteasomeDocking (molecular)Docking studieCaspasesDrug DesignPyrazinesProteolysisbiology.proteinCattlePeptidomimeticsProteasome InhibitorsLead compoundmedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct

High quality nano-patterned thin films of the coordination compound {Fe(pyrazine)[Pt(CN)4]} deposited layer-by-layer

2011

International audience; An optimised procedure was developed for the layer-by-layer deposition of the Hofmann clathrate-like coordination compound {Fe(pyrazine)[Pt(CN)4]} either as continuous or as nano-patterned thin films. Characterization of the thickness and topography of the thin films by atomic force microscopy (AFM) and by surface plasmon resonance (SPR) spectroscopy, which also yields the layer's refractive index and losses, are reported. We found that the films are of good optical quality and the results of both AFM and SPR experiments are in good agreement with the theoretical predictions of the films thicknesses.

Pyrazine010405 organic chemistryChemistryLayer by layerAnalytical chemistryGeneral Chemistry010402 general chemistry01 natural sciencesCatalysis0104 chemical scienceschemistry.chemical_compoundNano-Materials ChemistryThin filmSurface plasmon resonance[SPI.NANO]Engineering Sciences [physics]/Micro and nanotechnologies/MicroelectronicsSpectroscopyRefractive indexLayer (electronics)
researchProduct